Ocular Therapeutix announces workforce cut to focus on drug development

Must read

In a strategic move, Ocular Therapeutix (NASDAQ: NASDAQ:) has announced a reduction in its workforce, primarily affecting the research and development and technical operations departments. The decision, approved by the Board of Directors on May 29, 2024, will see the elimination of 37 full-time positions, which is approximately 13% of the company’s total workforce.

This initiative is aimed at reallocating resources towards the clinical development of AXPAXLI™ (axitinib intravitreal implant), also known as OTX-TKI, which is being developed for the treatment of wet age-related macular degeneration. The company has indicated that the restructuring is expected to be substantially completed within the second quarter of 2024.

Ocular Therapeutix estimates that the total restructuring costs will be in the range of $1.0 to $2.0 million. These costs will cover garden leave, severance benefits, and related expenses. The financial impact of these changes is anticipated to affect cash flow during the second and third quarters of the year.

As the company continues to review its business plan and evaluate the full implications of the workforce reduction, it acknowledges the possibility of additional restructuring costs. However, at this time, the company is unable to estimate any further expenses or charges.

The information in this article is based on the latest SEC filing by Ocular Therapeutix.

InvestingPro Insights

In light of Ocular Therapeutix’s recent strategic workforce reduction, current and prospective investors may find the following InvestingPro Insights particularly relevant. As the company reallocates its resources towards the development of AXPAXLI™, it’s important to consider the financial health and market performance of OCUL.

InvestingPro Data shows that Ocular Therapeutix holds a market capitalization of $909.2 million USD. Despite challenges, the company’s revenue has grown by 15.79% over the last twelve months as of Q1 2024. This indicates a level of resilience in generating income. However, the company’s gross profit margin stands at -21.04%, reflecting the current costs outweighing revenue.

One of the InvestingPro Tips for OCUL is that it holds more cash than debt on its balance sheet, which could provide a buffer during this restructuring phase. Additionally, the company’s liquid assets exceed its short-term obligations, suggesting that Ocular Therapeutix has the liquidity to meet immediate financial needs.

On the flip side, two analysts have revised their earnings downwards for the upcoming period, and OCUL is not expected to be profitable this year. With the recent workforce reduction, these metrics will be critical for investors to monitor as they may impact the company’s future performance.

For those interested in a deeper dive into OCUL’s financials and market performance, InvestingPro offers additional insights. There are more InvestingPro Tips available, providing a comprehensive analysis of Ocular Therapeutix’s financial health and future outlook. To access these tips and more detailed metrics, visit InvestingPro’s dedicated page for OCUL. Don’t forget to use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

More articles

Latest article